Clinical Trials Logo

Tobacco Use Disorder clinical trials

View clinical trials related to Tobacco Use Disorder.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06163872 Completed - Nicotine Dependence Clinical Trials

Doctors' Perspective on Tobacco Addiction

Start date: May 1, 2023
Phase:
Study type: Observational

ABSTRACT Aim: Our study aimed to determine the approaches of our physicians to the smoking habits of their patients other than those with pulmonary diseases. Method: Patients examined in different outpatient clinics of our hospital will be asked 7 questions about the doctor's approach to smoking habits. 1) Do you have information about smoking cessation clinic? 2) Has your doctor asked if you smoke? 3) Did he suggest you stop using it? 4) Did he inform you about the relationship between smoking and your disease? 5) Did he provide information about smoking cessation outpatient clinic services? 6) Have you ever thought about quitting smoking after your doctor's briefing? 7) Did you quit smoking after your doctor's briefing?

NCT ID: NCT06091826 Completed - Smoking Cessation Clinical Trials

Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)

PRECESTO
Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking. The primary objective is to assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the modified Cigarette Evaluation Questionnaire (mCEQ) "Smoking Satisfaction" (items 1, 2, and 12) subscale.

NCT ID: NCT05538702 Completed - Clinical trials for Nicotine Dependence, Cigarettes

Acute Oral Effects of Heated Tobacco Products

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Heated tobacco products (HTP) are devices which heat, but not burn tobacco. They do not produce cigarette smoke but rather an aerosol. HTPs are marketed as less harmful alternatives to smoking. Use and awareness of these devices have grown exponentially in recent years, with probably millions of people currently using them. There is very little literature about them, so it is quite important to study the effects caused on the human body by these products. The benefits and risks of HTP use are uncertain. There is no research on the acute oral effects of HTPs in the scientific literature.

NCT ID: NCT05477342 Completed - Clinical trials for Nicotine Dependence, Cigarettes

Reducing Nicotine Addiction in Adolescent Smokers

Start date: September 3, 2018
Phase: N/A
Study type: Interventional

Adolescents are at risk for tobacco use due to factors such as impulsivity, poor perception, desire to prove themselves, and insufficient neurological development. The Center of Disease (CDC) warns that if smoking continues at the current rate among young people, young people younger than 18 will die prematurely from a smoking-related disease The aim of this study was to comparison the effect of a board game and tobacco cessation education on reducing nicotine addiction in adolescents. A single-blind randomized controlled trial was used to evaluation the effect s of the different interventions on tobacco cessation. The 12 week interventions included: 1) Board Game (BG) and 2) Tobacco Cessation Education (TCE) developed based on Transtheoretical Model and 3) combined use of these two interventions (Cİ). All interventions were compared to Control Group(CG). "Fagerström Test for Nicotine Dependence (FNTD)" were used to collect data at baseline, at 8.week and at 12.week the intervention. "Assessment Of Stage Of Change Form (ASCF)" were used to collect data at baseline and at the end of each intervention (every two weeks one). Participants were consisted of students studying at a high school in Eskisehir in Turkey. In order to form the intervention groups, permission was obtained from the school principal and teacher of each class, and the students were informed about the purpose of the study and the participation criteria. It was done in information classes. Recruitment began in October 2018 and end in January 2019. Students who wanted to participate in the study were asked to send a short message to the investigator's private phone number. An automated response with a hyperlink was sent to a web page where information about the study was presented and students were asked to give informed consent at the push of a button. Students who agreed to participate were enrolled in a web-based questionnaire for egilibility screening.

NCT ID: NCT05473585 Completed - Smoking Clinical Trials

Impact of New Standards for Tobacco Products Among Dual E-Cigarette/Combusted Cigarette Users - Project 2

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate how limiting the nicotine content in regular cigarettes affects choices for regular cigarette and e-cigarette products. Eligible participants will be of legal age to purchase tobacco products and regularly use both e-cigarettes and regular cigarettes.

NCT ID: NCT05447156 Completed - Clinical trials for Tobacco Use Disorder

QuitGuide for American Indians: Aims 2 & 3

Start date: December 14, 2022
Phase: N/A
Study type: Interventional

Aim 2: To assess the preliminary feasibility and acceptability of a tailored smoking cessation app prototype (here forward called tailored QuitGuide) among American Indian (AI) smokers. Aim 3: To test feasibility, acceptability, and preliminary efficacy of the tailored QuitGuide for smoking cessation among AIs.

NCT ID: NCT05279053 Completed - Cigarette Smoking Clinical Trials

Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers

Start date: April 1, 2021
Phase:
Study type: Observational

The proposed study will evaluate sex differences in whole-brain glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu will be measured in almost the entire brain, with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in behavioral states linked to tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) will be measured for female participants to determine relationships between brain Glu and this hormone. Whole-brain Glu will be measured in 60 smokers (30 men, 30 women) twice, after overnight (~12 h) abstinence and after participants smoke the first cigarette of the day.

NCT ID: NCT05271175 Completed - Smoking Cessation Clinical Trials

Accelerated iTBS in Smoking Cessation

Start date: April 19, 2019
Phase: N/A
Study type: Interventional

Cigarette smoking is one of the foremost causes of preventable disease and premature death. In 2014, 68% of adult smokers wanted to quit smoking and in 2017, 55.1% of adult smokers had made a quit attempt. However, only a small percentage of adult smokers (7,4%) achieved to quit smoking. Transcranial magnetic stimulation (TMS) is a novel, powerful, non-invasive brain stimulation therapy. This study used Theta Burst Stimulation (TBS), a newer form of rTMS protocol that can be delivered in a shorter duration compared to the standard rTMS protocol, while delivering a comparable number of pulses. It is a tolerable, powerful, and useful tool in non-invasive brain stimulation therapies. This double-blind randomized control trial evaluated the efficacy of 4 iTBS sessions per day during 5 consecutive days over the left DLPFC in smoking cessation. Moreover, it investigated whether the exposure to smoking-related cues during the rTMS treatment, compared to neutral cues impact cigarette craving.

NCT ID: NCT05210608 Completed - Clinical trials for Tobacco Use Disorder/Cigarette Smoking

Working Memory Training on Delay Discounting Among Cigarette Smokers

RTA
Start date: November 30, 2021
Phase: N/A
Study type: Interventional

Despite widespread awareness of significant negative health consequences, cigarette smoking remains the leading cause of preventable morbidity and mortality in the US (Creamer et al., 2019; Jamal, 2018). Moreover, the highest rate of smoking and heaviest burden of smoking-related illness occurs among low-socioeconomic status (SES) individuals relative to higher SES groups (Businelle et al., 2010; Clegg et al., 2009). Low SES individuals are also 40% less likely to succeed in quitting smoking when they attempt to do so (National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014). One potential explanation for the disparity in rate of smoking and successful quit attempts may be differences in individual rates of delay discounting (DD), i.e., the degree to which rewards loses their value as the delays to their receipt increase (Odum, 2011). A proposed way to reduce steep DD and, potentially, substance use has been computer training for working memory, which has shown favorable results in a sample of individuals with stimulant dependence (Bickel et al., 2011) and substance use broadly (Felton et al., 2019), with the latter even showing decreases in cigarette smoking in a subset of the sample.

NCT ID: NCT05159934 Completed - Nicotine Dependence Clinical Trials

Nicotine Differences in Smokers

Start date: February 16, 2022
Phase: Phase 1
Study type: Interventional

The primary aim of this project is to determine the threshold dose of nicotine, which the smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco cigarette or electronic cigarette), allowing precise and reproducible nicotine delivery. Four nicotine doses (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) which are within the range of nicotine doses that are delivered by cigarettes with very low to regular nicotine content. These doses will be delivered as a cluster of 4 pulsed-nicotine infusions of 2 sec duration with a 28 sec interval between each dose.